{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:35:34Z","timestamp":1790004934023,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.amjcard.2017.07.047","type":"journal-article","created":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T15:42:23Z","timestamp":1501515743000},"page":"1521-1527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Effect of the Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus"],"prefix":"10.1016","volume":"120","author":[{"given":"Naveed","family":"Sattar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handrean","family":"Soran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Uhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcoli","family":"Cyrille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ransi","family":"Somaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3139-1836","authenticated-orcid":false,"given":"David","family":"Preiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.07.047_bib0010","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0020","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1007\/s00125-014-3374-x","article-title":"Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis","volume":"57","author":"Erqou","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0025","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.2337\/db14-1710","article-title":"Using genetic variants to assess the relationship between circulating lipids and type 2 diabetes","volume":"64","author":"Fall","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0030","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamacardio.2016.1884","article-title":"Association of lipid fractions with risks for coronary artery disease and diabetes","volume":"1","author":"White","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOL.0b013e3283587563","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibition","volume":"23","author":"Marais","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0045","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1517\/14712598.2014.902929","article-title":"Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin\/kexin type 9: the available clinical evidence","volume":"14","author":"Cicero","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2213-8587(16)00003-6","article-title":"Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data","volume":"4","author":"Sattar","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/dom.12788","article-title":"Evaluation of the efficacy, safety, and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome","volume":"19","author":"Blom","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0060","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Fourier steering committee and investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0065","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2016.14568","article-title":"Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis","volume":"316","author":"Lotta","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study","volume":"5","author":"Schmidt","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0075","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0080","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0085","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0090","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0095","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0100","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0105","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0110","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0115","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0125","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1253\/circj.CJ-14-0130","article-title":"Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk\u2013primary results from the phase 2 YUKAWA study","volume":"78","author":"Hirayama","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","article-title":"A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk","volume":"117","author":"Kiyosue","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0135","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s40064-016-1892-3","article-title":"Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting","volume":"5","author":"Dent","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0140","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0145","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","article-title":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies","volume":"37","author":"Colhoun","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0150","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.07.047_bib0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00125-015-3802-6","article-title":"Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)","volume":"59","author":"Livingstone","year":"2016","journal-title":"Diabetologia"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917312201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917312201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T17:25:51Z","timestamp":1535563551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917312201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0002914917312201"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.07.047","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of the Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.07.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}